Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N145

UPID:
LGI3_HUMAN

ALTERNATIVE NAMES:
LGI1-like protein 4; Leucine-rich glioma-inactivated protein 3

ALTERNATIVE UPACC:
Q8N145; A5PLP2; Q86TL4; Q8N296

BACKGROUND:
The protein Leucine-rich repeat LGI family member 3, known alternatively as LGI1-like protein 4 or Leucine-rich glioma-inactivated protein 3, is implicated in neuronal exocytosis regulation. Its gene is identified by the accession Q8N145, highlighting its significance in neurobiology.

THERAPEUTIC SIGNIFICANCE:
This protein's malfunction is associated with intellectual developmental disorder with muscle tone abnormalities and distal skeletal defects. The exploration of Leucine-rich repeat LGI family member 3's function offers promising avenues for the development of novel therapeutic interventions for related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.